Predicting treatable traits for long-acting bronchodilators in patients with stable COPD

References

• LozanoRNaghaviMForemanKGlobal and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010Lancet201238098592095212823245604
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global Strategy for the Diagnosis, Management and Prevention of COPD2017 Available from: http://goldcopd.org/Accessed October 20, 2017
   Google Scholar
• TashkinDPCooperCBThe role of long-acting bronchodilators in the management of stable COPDChest2004125124925914718448
   PubMed Web of Science ®Google Scholar
• MahlerDADonohueJFBarbeeRAEfficacy of salmeterol xinafoate in the treatment of COPDChest1999115495796510208192
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• VinckenWvan NoordJAGreefhorstAPImproved health outcomes in patients with COPD during 1 yr’s treatment with tiotropiumEur Respir J200219220921611871363
   PubMed Web of Science ®Google Scholar
• SantusPRadovanovicDPaggiaroPWhy use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterolEur J Intern Med201526637938426049917
   PubMed Web of Science ®Google Scholar
• OkudanNGokMGokbelHSuerdemMSingle dose of tiotropium improves the 6-minute walk distance in chronic obstructive pulmonary diseaseLung2006184420120417006746
   PubMed Web of Science ®Google Scholar
• BrouillardCPepinVMilotJLacasseYMaltaisFEndurance shuttle walking test: responsiveness to salmeterol in COPDEur Respir J200831357958418057052
   PubMed Web of Science ®Google Scholar
• BarrRGBourbeauJCamargoCARamFSTiotropium for stable chronic obstructive pulmonary disease: a meta-analysisThorax2006611085486216844726
   PubMed Web of Science ®Google Scholar
• JonesPWBarnesNVogelmeierCLawrenceDKramerBEfficacy of indacaterol in the treatment of patients with COPDPrim Care Respir J201120438038821785813
   PubMedGoogle Scholar
• MiravitllesMSoler-CatalunaJJCalleMSorianoJBTreatment of COPD by clinical phenotypes: putting old evidence into clinical practiceEur Respir J20134161252125623060631
   PubMed Web of Science ®Google Scholar
• AndersonDMacneeWTargeted treatment in COPD: a multi-system approach for a multi-system diseaseInt J Chron Obstruct Pulmon Dis2009432133519750192
   PubMedGoogle Scholar
• AnthonisenNRLindgrenPGTashkinDPKannerREScanlonPDConnettJEBronchodilator response in the lung health study over 11 yearsEur Respir J2005261455115994388
   PubMed Web of Science ®Google Scholar
• LehmannSBakkePSEideGEHumerfeltSGulsvikABronchodilator reversibility testing in an adult general population; the importance of smoking and anthropometrical variables on the response to a beta2-agonistPulm Pharmacol Ther200619427228016169762
   PubMed Web of Science ®Google Scholar
• SchermerTHeijdraYZadelSFlow and volume responses after routine salbutamol reversibility testing in mild to very severe COPDRespir Med200710161355136217098407
   PubMed Web of Science ®Google Scholar
• CherubiniEEspositoMCScozziDGenetic polymorphism of CHRM2 in COPD: clinical significance and therapeutic implicationsJ Cell Physiol201623181745175126633752
   PubMed Web of Science ®Google Scholar
• WechslerMELehmanELazarusSCbeta-Adrenergic receptor polymorphisms and response to salmeterolAm J Respir Crit Care Med2006173551952616322642
   PubMed Web of Science ®Google Scholar
• BleeckerERMeyersDABaileyWCADRB2 polymorphisms and budesonide/formoterol responses in COPDChest2012142232032822383665
   PubMed Web of Science ®Google Scholar
• KimWJOhYMSungJLung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary diseaseLung2008186638138618758858
   PubMed Web of Science ®Google Scholar
• DonohueJFMinimal clinically important differences in COPD lung functionCOPD20052111112417136971
   PubMedGoogle Scholar
• KumarPHenikoffSNgPCPredicting the effects of coding non-synonymous variants on protein function using the SIFT algorithmNat Protoc2009471073108119561590
   PubMed Web of Science ®Google Scholar
• AutonABrooksLDDurbinRMA global reference for human genetic variationNature20155267571687426432245
   PubMed Web of Science ®Google Scholar
• NakkenSAlsethIRognesTComputational prediction of the effects of non-synonymous single nucleotide polymorphisms in human DNA repair genesNeuroscience200714541273127917055652
   PubMed Web of Science ®Google Scholar
• YuETHadiMZBioinformatic processing to identify single nucleotide polymorphism that potentially affect Ape1 functionMutat Res2011722214014620633698
   PubMed Web of Science ®Google Scholar
• AroraSHuwePJSikderRFunctional analysis of rare variants in mismatch repair proteins augments results from computation-based predictive methodsCancer Biol Ther201718751953328494185
   PubMed Web of Science ®Google Scholar
• LeeKHBaikSYLeeSYParkCHParkPJKimJHGenome sequence variability predicts drug precautions and withdrawals from the marketPLoS One2016119e016213527690231
   PubMed Web of Science ®Google Scholar
• OhnoTWadaSHanadaSSawaguchiHMurakiMTohdaYEfficacy of indacaterol on quality of life and pulmonary function in patients with COPD and inhaler device preferencesInt J Chron Obstruct Pulmon Dis2014910711424489464
   PubMed Web of Science ®Google Scholar
• MoitaJBarbaraCCardosoJTiotropium improves FEV1 in patients with COPD irrespective of smoking statusPulm Pharmacol Ther200821114615117693107
   PubMed Web of Science ®Google Scholar
• HizawaNMakitaHNasuharaYBeta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPDChest200713251485149217890463
   PubMed Web of Science ®Google Scholar
• ProskocilBJFryerADBeta2-agonist and anticholinergic drugs in the treatment of lung diseaseProc Am Thorac Soc200524305310 discussion 311–30216267353
   PubMedGoogle Scholar
• CazzolaMMolimardMThe scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPDPulm Pharmacol Ther201023425726720381630
   PubMed Web of Science ®Google Scholar
• KurianNHallCJWilkinsonGFSullivanMTobinABWillarsGBFull and partial agonists of muscarinic M3 receptors reveal single and oscillatory Ca2+ responses by beta 2-adrenoceptorsJ Pharmacol Exp Ther2009330250251219420300
   PubMed Web of Science ®Google Scholar
• BelmonteKECholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary diseaseProc Am Thorac Soc200524297304 discussion 311–29216267352
   PubMedGoogle Scholar
• BhattacharyaSTyagiSSrisumaSPeripheral blood gene expression profiles in COPD subjectsJ Clin Bioinform20111112
   Google Scholar
• PoliskaSCsankyESzantoAChronic obstructive pulmonary disease-specific gene expression signatures of alveolar macrophages as well as peripheral blood monocytes overlap and correlate with lung functionRespiration201181649951021430361
   PubMed Web of Science ®Google Scholar
• EdmistonJSArcherKJScianMJGene expression profiling of peripheral blood leukocytes identifies potential novel biomarkers of chronic obstructive pulmonary disease in current and former smokersBiomarkers201015871573020887155
   PubMed Web of Science ®Google Scholar
• BahrTMHughesGJArmstrongMPeripheral blood mononuclear cell gene expression in chronic obstructive pulmonary diseaseAm J Respir Cell Mol Biol201349231632323590301
   PubMed Web of Science ®Google Scholar
• AgustiASorianoJBCOPD as a systemic diseaseCOPD20085213313818415812
   PubMedGoogle Scholar
• IsraelEDrazenJMLiggettSBThe effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthmaAm J Respir Crit Care Med20001621758010903223
   PubMed Web of Science ®Google Scholar
• IsraelEChinchilliVMFordJGUse of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trialLancet200436494441505151215500895
   PubMed Web of Science ®Google Scholar
• HizawaNPharmacogenetics of chronic obstructive pulmonary diseasePharmacogenomics201314101215122523859575
   PubMed Web of Science ®Google Scholar
• HershCPPharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunitiesPharmacogenomics201011223724720136362
   PubMed Web of Science ®Google Scholar
• CondreayLHuangLHarrisEGenetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary diseaseRespir Med201611412312627109822
   PubMed Web of Science ®Google Scholar
• GeneCardsSCN10A Gene Available from: http://www.genecards.org/cgi-bin/carddisp.pl?gene=SCN10AAccessed October 20, 2017
   Google Scholar
• GeneCardsRHOQ Gene Available from: http://www.genecards.org/cgi-bin/carddisp.pl?gene=RHOQ&keywords=rhoqAccessed October 20, 2017
   Google Scholar